Exelixis Inc (NASDAQ:EXEL)
During the Trading Day
| 4.61 |  +0.12 / +2.67% |
Data as of 4:00pm ET | Day’s Change |
During After-Hours Switch to standard view »
| 4.60 |  -0.01 / -0.22% |
Volume: 20,000 |
Latest EXEL News | Press Releases
No recent news for Exelixis Inc.
Today’s Trading
| Previous close | 4.49 |
| Today’s open | 4.50 |
| Day’s range | 4.50 - 4.63 |
| Volume | 922,200 |
| Average volume (3 months) | 1,405,680 |
| Market cap | $825.3M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/21/2013
Growth & Valuation
| Earnings growth (last year) | -258.62% |
| Earnings growth (this year) | -31.96% |
| Earnings growth (next 5 years) | 0.00% |
| Revenue growth (last year) | -83.62% |
| P/E ratio | NM |
| Price/Sales | 15.42 |
| Price/Book | 2.78 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| BRLIBio-Reference Labora... | +0.35 | +1.16% |
| NXTMNxstage Medical Inc | +0.12 | +0.90% |
| KERXKeryx Biopharmaceuti... | +0.11 | +1.39% |
| AMRNAmarin Corporation P... | -0.07 | -0.99% |
Data as of 4:00pm ET, 05/21/2013
Financials
| Next reporting date | August 6, 2013 |
| EPS forecast (this quarter) | -$0.29 |
| Annual revenue (last year) | $47.5M |
| Annual profit (last year) | -$147.6M |
| Net profit margin | -311.16% |
Profile
Sector Health Technology |
Industry Biotechnology |
Chairman Stelios B. Papadopoulos, PhD, MBA |
President, Chief Executive Officer & Director Michael M. Morrissey, PhD |
Corporate headquarters South San Francisco, California |
Forecasts
